Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study. Neal, J. W., Lim, F., Felip, E., Gentzler, R. D., Patel, S. B., Baranda, J., Fang, B., Squillante, C., Simonelli, M., Werneke, S., Curran, D., Ponce Aix, S. AMER SOC CLINICAL ONCOLOGY. 2020

View details for Web of Science ID 000560368303508